VERNON HILLS, Ill.--(BUSINESS WIRE)--Elorac, Inc., a rapidly growing specialty pharmaceutical company focused on the treatment of dermatological disorders, announced that the USPTO has issued U.S. Patent No. 8,604,047 entitled “Method and Composition for Treating Nodulocystic and Conglobate Acne Vulgaris.” This patent provides for once-weekly oral administration of selective inhibitors of type 1 and/or type 2 isoforms of steroid 5a-reductase to patients with nodulocystic and conglobate acne vulgaris. These are the most severe types of acne vulgaris, affecting some 8-10 million patients in the United States and producing scarring and substantial functional disability as a result of the scars.
Help employers find you! Check out all the jobs and post your resume.
